| ¿µ¹® | digestive system | ÇÑ±Û | ¼Òȱâ°èÅë |
|---|---|---|---|
| ¼³¸í | ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼ ºÎ¸£´Â ¸». |
||
| ¿µ¹® | nervous system | ÇÑ±Û | ½Å°æ°è |
|---|---|---|---|
| ¼³¸í | ¿©·¯ ±â°üµéÀÇ ¼·Î°£ »óÈ£¿¬°áü°è°¡ ¹Ù·Î ½Å°æ°èÀÌ´Ù. ¿©±â¿¡´Â ÁßÃ߽Űæ°è(central nerve system: CNS)¿Í ¸»ÃʽŰæ°è(peripheral nerve system: PNS)°¡ Àִµ¥, ÁßÃ߽Űæ°è¶õ ³ú¿Í ô¼ö¸¦ ¸»ÇÑ´Ù. ±×¸®°í ¸»ÃʽŰæ°è¿¡´Â 12½ÖÀÇ ³ú½Å°æ(cranial nerve: ³ú¿¡¼ ±â½ÃÇÏ¿© ÁÖ·Î ¾ó±¼ºÎÀ§¿Í ¸ñ ºÎÀ§¿¡ ºÐÆ÷ÇÑ´Ù)°ú 31½ÖÀÇ Ã´¼ö½Å°æ(spinal nerve:spinal cord¿¡¼ °¢±â ¾çÂÊÀ¸·Î ½ÖÀ» ÀÌ·ç¾î ³ª¿À´Âµ¥ ÁÖ·Î ¸ñÀÌÇϺÎÀ§ÀÇ ½Åü °¢ºÎºÐÀ¸·Î ºÐÆ÷ÇÏ°Ô µÈ´Ù)À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¶ÇÇÑ ¸»ÃʽŰæ°è´Â 3°¡ÁöÀÇ ½Å°æÁ¶Á÷µé·Î ±¸¼ºµÇ¾î Àִµ¥ ¾Õ¿¡¼ ¸»ÇÑ ³ú½Å°æ°ú ô¼ö½Å°æ¿Ü¿¡ ÀÚÀ²½Å°æ°è°¡ ¿©±â¿¡ ÇØ´çµÈ´Ù. ÀÚÀ²½Å°æ°è´Â ´Ù½Ã ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æÀ¸·Î ³ª´µ¾îÁ® ¼·Î°£ÀÇ ¿Ã¹Ù¸¥ »óÈ£ÀÛ¿ëÀ¸·Î »ýü ¿©·¯ °¡Áö ÀÛ¿ëÀ» ¼öÇàÇÑ´Ù. |
||
| ¿µ¹® | cardiovascular system | ÇÑ±Û | ½ÉÀåÇ÷°ü°è |
|---|---|---|---|
| ¼³¸í | ½ÅüÀÇ Ç÷¾×¼øÈ¯À» ´ã´çÇÏ´Â ±â°ü. Áï ½ÉÀå°ú Ç÷°üÀ» ÅëÄªÇØ¼ À̸£´Â ¸»ÀÌ´Ù. |
||
| ¿µ¹® | autonomic nervous system | ÇÑ±Û | ÀÚÀ²½Å°æ°è |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ÀÇÁö¿Í °ü°è¾øÀÌ, ħÀ» È긮°Å³ª ¼Òȿ µî°ú °°Àº ½º½º·Î Á¶Á¤ÀÌ µÇ¾î ¿òÁ÷ÀÌ´Â ½Å°æ°èÀÌ¸ç ¿©±â¿¡´Â ´ÙÀ½°ú °°Àº µÎ °¡Áö°¡ ÀÖ´Ù. 1.±³°¨½Å°æ°è(sympathetic nervous system)-»ç¶÷ÀÌ À§Çè»óÅ¿¡ À̸£·¶À» °æ¿ì¿¡ ÈïºÐÀÌ µÇ´Â ÀÚÀ²½Å°æ°è. Áï ½É¹Ú¼öÀÇ Áõ°¡, ¼Òȱ⠿ÀÇ °¨¼Ò µîÀÇ ÀÏÀÌ À̰÷À» ÅëÇØ¼ ÀϾÙ. ±³°¨½Å°æÀÌ ÈïºÐµÇ¸é ±³°¨½Å°æÀÇ ¸»´Ü¿¡¼ epinephrine, norepinephrine µîÀÇ ¹°ÁúÀÌ ºÐºñµÇ°í À̰͵鿡 ÀÇÇØ¼ ¸»ÃÊÀå±â°¡ º¯È¸¦ ÀÏÀ¸Å²´Ù. ÇÏÁö¸¸ Àå±â¿¡ µû¶ó¼ epinephrineÀ̳ª norepinephrineÀÇ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ¾î¼ ¿©·¯ °¡Áö ´Ù¸¥ Àå±âÀÇ ¹ÝÀÀÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¼ö¿ëü´Â ´ÙÀ½°ú °°´Ù. -¾ËÆÄ¼ö¿ëü(alpha-receptor): ¸»ÃÊÇ÷°üÀÇ ¼öÃà, ±â°üÁöÀÇ ¼öÃà, µ¿°øÀÇ ±ÙÀ°ÀÇ ¼öÃà -º£Å¸1¼ö¿ëü(beta 1-receptor): ½ÉÀå¿¡ Á¸ÀçÇÏ´Â ¼ö¿ëü, ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. -º£Å¸2¼ö¿ëü(beta 2-receptor): Ç÷°üÀÇ ÀÌ¿Ï, ±â°üÁöÀÇ ÀÌ¿Ï, Áï °¢ Àå±âµéÀº ±× Àå±â°¡ °¡Áö°í ÀÖ´Â ±³°¨½Å°æÀÇ ¼ö¿ëü¿¡ µû¶ó ±³°¨½Å°æÀÇ ÈïºÐ(±³°¨½Å°æ ¸»´Ü¿¡¼ÀÇ epinephrineÀÇ ºÐºñ)¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ´Þ¶óÁø´Ù(¿¹-±³°¨½Å°æÀÌ ÈïºÐ½Ã¿¡ beta 1-¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Â ½ÉÀåÀº »¡¸® ¶Ù°Ô µÈ´Ù. ±³°¨½Å°æ ÈïºÐ½Ã¿¡ µ¿°øÀÇ ±ÙÀ°ÀÌ ¼öÃàÇØ¼ µ¿°øÀÇ Å©±â°¡ Ä¿Áø´Ù) 2.ºÎ±³°¨½Å°æ°è(parasympathetic nervous system)-±³°¨½Å°æ°ú ¹Ý´ë·Î ÀÛ¿ëÇÑ´Ù. Áï »ç¶÷ÀÌ Á¹¸®°Å³ª ½¯ °æ¿ì¿¡ ÈïºÐÇÑ´Ù. ºÎ±³°¨½Å°æÀÌ ÈïºÐÇÒ ¶§¿¡´Â ½Å°æÀÇ ¸»´Ü¿¡¼ ¾Æ¼¼Ä¥Äݸ°ÀÇ ºÐºñ°¡ ÀϾ°í À̰ÍÀ¸·Î ÀÎÇØ¼ °¢ Àå±âÀÇ º¯È°¡ ÀϾÙ. |
||
| ¿µ¹® | TNM staging system | ÇÑ±Û | Á¾¾çº´±âºÐ·ù°èÅë |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤ÇÏ´Â ÇÑ ¹æ¹ý. T´Â Tumor(Á¾¾ç)¸¦ ¶æÇÏ¸ç ¿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀÇ Ä§À±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î ħÀ±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù. NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç ħ¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù. MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇÏ¸ç ¿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù. ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀÎ º´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù. |
||
| GDS | geriatric depression scale; Global Deterioration Scale; Gordon Diagnostic System [for attention diso... |
|---|---|
| MDS | Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system... |
| MPS | meconium plug syndrome; medial premotor system; Member of the Pharmaceutical Society; microbial prof... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| HIVD | Herniation(Herniated) of Inter-Vertebral Disc - Cervical HIVD &... |
| child reactive disorders | Reactions to an event or set of events which are considered to be of pathological degree, that have not developed into a neurosis, psychosis, or personality disorder with fixed patterns. (12 Dec 1998) |
|---|---|
| peroxisomal disorders | A heterogeneous group of inherited metabolic disorders in which peroxisomes are either defective or totally lacking and/or there is a dysfunction of single or multiple peroxisomal enzymes. Patients show metabolic defects in all the major biosynthetic peroxisomal pathways, especially failure to synthesise ether lipids, or to oxidise long-chain fatty acids, and accumulate bile acid precursors. The disorders include zellweger syndrome, infantile refsum disease, rhizomelic chondrodysplasia (chondrodysplasia punctata, rhizomelic), and hyperpipecolic acidemia. (12 Dec 1998) |
| personality disorders | A major deviation from normal patterns of behaviour. (12 Dec 1998) |
| growth disorders | Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. The concept includes both acceleration and retardation of growth. (12 Dec 1998) |
| phagocytic dysfunction disorders immunodeficiency | Suppression in number or function of phagocytic cells such as in chronic granulomatous disease. Synonym: phagocytic dysfunction disorders immunodeficiency. Origin: L. Phagedaena, Gr Phago, To eat. (05 Mar 2000) |
| ciliary motility disorders | Disorders characterised by abnormal ciliary movement in the nose, paranasal sinuses, respiratory tract, and spermatozoa. Electron microscopy of the cilia shows that dynein arms are missing. The disorders manifest as kartagener triad (kartagener's syndrome), chronic respiratory disorders, chronic sinusitis, and/or chronic otitis. (12 Dec 1998) |
| phobic disorders | Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognises the fear as excessive or unreasonable. (12 Dec 1998) |
| civil disorders | Deliberate and planned acts of unlawful behaviour engaged in by aggrieved segments of the population in seeking social change. (12 Dec 1998) |
| phosphorus metabolism disorders | Disorders in the processing of phosphorus in the body: its absorption, transport, storage, and utilization. (12 Dec 1998) |
| photosensitivity disorders | Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy. (12 Dec 1998) |
| mood disorders | Those disorders that have a disturbance in mood as their predominant feature. (12 Dec 1998) |
| combat disorders | Neurotic reactions to unusual, severe, or overwhelming military stress. (12 Dec 1998) |
| communication disorders | Disorders characterised by the individual's inability to comprehend or share ideas or feelings because of impairment of language, speech, or hearing. (12 Dec 1998) |
| motor skills disorders | Marked impairments in the development of motor coordination such that the impairment interferes with activities of daily living. (12 Dec 1998) |
| platelet function disorders | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (31 Dec 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|